July 7, 2026 · Blood · DOI: 10.1182/blood.2025032122

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma

Listen to this summary

The authors aimed to evaluate the safety and efficacy of concurrent administration of BCMA and GPRC5D CAR T cells in patients with advanced multiple myeloma. In a phase I trial involving 15 heavily pre-treated patients, they found that the co-infusion resulted in a high overall response rate of 78% and a median progression-free survival of 18.2 months, while noting potential resistance mechanisms such as antigen loss and limited expansion of CAR populations. The study highlights the complexities of dual-targeted therapies in managing multiple myeloma.

Sham Mailankody, Sneha Mitra, Kevin Herrera, Bachisio Ziccheddu, Briana Cadzin, Ozgur Can Eren, Tasmin Farzana, Tahmin Ullah, Jonathan Landa, Andriy Derkach, Jagrutiben Chaudhari, Devin McAvoy, Kinga Hosszu, Gunjan L Shah, Heather J Landau, Francesco Maura, Ahmet Dogan, Sergio A Giralt, Xiuyan Wang, Michel Sadelain, Eric L Smith, Renier J Brentjens, Christina S Leslie, Saad Z Usmani, Karlo Perica

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play